206 related articles for article (PubMed ID: 34435581)
1. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
Zhao M; Zhang J; Xu Y; Liu J; Ye J; Wang Z; Ye D; Feng Y; Xu S; Pan W; Wang M; Wan J
Int Immunopharmacol; 2021 Oct; 99():108046. PubMed ID: 34435581
[TBL] [Abstract][Full Text] [Related]
2. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
3. NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation.
Li S; Lin Q; Shao X; Mou S; Gu L; Wang L; Zhang Z; Shen J; Zhou Y; Qi C; Jin H; Pang H; Ni Z
Exp Cell Res; 2019 Oct; 383(1):111488. PubMed ID: 31276670
[TBL] [Abstract][Full Text] [Related]
4. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages.
Zeng W; Wu D; Sun Y; Suo Y; Yu Q; Zeng M; Gao Q; Yu B; Jiang X; Wang Y
Sci Rep; 2021 Sep; 11(1):19305. PubMed ID: 34588488
[TBL] [Abstract][Full Text] [Related]
5. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
6. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca
Suetomi T; Willeford A; Brand CS; Cho Y; Ross RS; Miyamoto S; Brown JH
Circulation; 2018 Nov; 138(22):2530-2544. PubMed ID: 30571348
[TBL] [Abstract][Full Text] [Related]
7. The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis.
Wang M; Pan W; Wei C; Liu J; Zhang J; Yu J; Zhao M; Xu S; Ye J; Wang Z; Ye D; Feng Y; Xu Y; Wan J
Drug Des Devel Ther; 2023; 17():3073-3083. PubMed ID: 37849783
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy.
Ma S; Feng J; Lin X; Liu J; Tang Y; Nie S; Gong J; Wang L
Oxid Med Cell Longev; 2021; 2021():5546867. PubMed ID: 34567409
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
10. MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure.
Jiang X; Yang F; Ou D; Huang L; Li H; Lang M
Bioengineered; 2022 Apr; 13(4):8593-8604. PubMed ID: 35287557
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-κB-mediated-MAPK and NLRP3-caspase pathways.
Wang X; Chen S; Zhao L; Shi X
Int Immunopharmacol; 2021 Aug; 97():107506. PubMed ID: 34022766
[TBL] [Abstract][Full Text] [Related]
12. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
[TBL] [Abstract][Full Text] [Related]
13. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
[TBL] [Abstract][Full Text] [Related]
14. The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence.
Shi Y; Zhao L; Wang J; Liu S; Zhang Y; Qin Q
Eur J Pharmacol; 2022 Dec; 937():175364. PubMed ID: 36336012
[TBL] [Abstract][Full Text] [Related]
15. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
16. Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome.
He W; Wei J; Liu X; Zhang Z; Huang R; Jiang Z
Sci Rep; 2024 May; 14(1):11824. PubMed ID: 38782946
[TBL] [Abstract][Full Text] [Related]
17. Untargeted metabolomics and lipidomics uncovering the cardioprotective effects of Huanglian Jiedu Decoction on pathological cardiac hypertrophy and remodeling.
Chen QQ; Wang FX; Cai YY; Zhang YK; Fang JK; Qi LW; Zhang L; Huang FQ
J Ethnopharmacol; 2021 Apr; 270():113646. PubMed ID: 33264659
[TBL] [Abstract][Full Text] [Related]
18. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
19. Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression.
Li R; Lu K; Wang Y; Chen M; Zhang F; Shen H; Yao D; Gong K; Zhang Z
Biochem Biophys Res Commun; 2017 Mar; 485(1):69-75. PubMed ID: 28202417
[TBL] [Abstract][Full Text] [Related]
20. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M
Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
